In addition, it would be of interest to the anti-diabetic retinopathy effect of erianin via ERK1/2–NF-κB and ERK1/2-HIF-1α-VEGF/VEGFR2 signaling pathway, which inhibited VEGF expression, retinal neovascularization and microglia activation. Here, VEGFA is linked to diabetic retinopathy.